Breast cancer could be detected up to five years before there are any clinical signs of it, using a blood test that identifies the body’s immune response to substances produced by tumour cells, according to new research presented at the 2019 NCRI Cancer Conference today (Sunday).
Cancer cells produce proteins called antigens that trigger the body to make antibodies against them – autoantibodies. Researchers at the University of Nottingham (UK) have found that these tumour-associated antigens (TAAs) are good indicators of cancer, and now they have developed panels of TAAs that are known already to be associated with breast cancer to detect whether or not there are autoantibodies against them in blood samples taken from patients.
In a pilot study the researchers, who are part of the Centre of Excellence for Autoimmunity in Cancer (CEAC) group at the School of Medicine, University of Nottingham, took blood samples from 90 breast cancer patients at the time they were diagnosed with breast cancer and matched them with samples taken from 90 patients without breast cancer (the control group).
They used screening technology (protein microarray) that allowed them to screen the blood samples rapidly for the presence of autoantibodies against 40 TAAs associated with breast cancer, and also 27 TAAs that were not known to be linked with the disease.
Presenting the research at the NCRI Conference, Ms Daniyah Alfattani, a PhD student in the group, said: “The results of our study showed that breast cancer does induce autoantibodies against panels of specific tumour-associated antigens. We were able to detect cancer with reasonable accuracy by identifying these autoantibodies in the blood.”
The researchers identified three panels of TAAs against which to test for autoantibodies. The accuracy of the test improved in the panels that contained more TAAs. The panel of five TAAs correctly detected breast cancer in 29% of the samples from the cancer patients and correctly identified 84% of the control samples as being cancer-free. The panel of seven TAAs correctly identified cancer in 35% of cancer samples and no cancer in 79% of control samples. The panel of nine antigens correctly identified cancer in 37% of cancer samples and no cancer in 79% of the controls.
“We need to develop and further validate this test,” said Ms Alfattani. “However, these results are encouraging and indicate that it’s possible to detect a signal for early breast cancer. Once we have improved the accuracy of the test, then it opens the possibility of using a simple blood test to improve early detection of the disease.”
The researchers are now testing samples from 800 patients against a panel of nine TAAs, and they expect the accuracy of the test to improve with these larger numbers.
“A blood test for early breast cancer detection would be cost effective, which would be of particular value in low and middle income countries. It would also be an easier screening method to implement compared to current methods, such as mammography,” said Ms Alfattani.
The researchers estimate that, with a fully-funded development programme, the test might become available in the clinic in about four to five years.
A similar test for lung cancer is currently being tested in a randomised controlled trial in Scotland, involving 12,000 people at high risk of developing lung cancer because they smoke. They have been randomised to have (or not) an autoantibody blood test called ELISA (Early CDT-Lung). Participants who test positive for the autoantibodies are then followed up with a CT scan every two years in order to detect lung cancer in its early stages when it is easier to treat.
The CEAC group is also working on similar tests for pancreatic, colorectal and liver cancers. Solid tumours like these, as well as lung and breast cancer, represent around 70% of all cancers.
“A blood test capable of detecting any of these cancers at an early stage is the over-riding objective of our work,” concluded Ms Alfattani.
Dr Iain Frame, CEO of NCRI said: “Early diagnosis using simple, non-invasive ways of detecting the first signs of cancer is a key strategic priority for NCRI and something we’d all like to see working in practice. The results from this pilot study for a blood test to detect early breast cancer are promising and build on this research group’s expertise in other cancers, such as lung cancer. It’s obviously early days but we look forward to seeing the results from the larger group of patients that are now being investigated.”
The Latest on: Breast cancer
via Google News
The Latest on: Breast cancer
- Roche : Late-stage Study On Breast Cancer Fails To Meet Primary Endpointon August 6, 2020 at 8:14 pm
(RTTNews) - Roche (RHHBY) said that Phase III IMpassion131 study did not meet statistical significance on its primary endpoint of progression-free survival for the initial treatment of people with ...
- Delay in breast cancer operations appears non-life-threatening for early-stage diseaseon August 6, 2020 at 9:12 am
A new breast cancer study brings reassuring findings for women with early-stage breast cancer who were forced to delay their cancer operations because of the Coronavirus Disease 2019 (COVID-19) ...
- Study: Many older Americans get cancer screens they don't needon August 6, 2020 at 7:18 am
Contrary to recommendations, many Americans are getting screened for cancer even when old age or poor health would likely render such screenings risky and pointless, new research finds.
- Gene could predict treatment response in certain breast cancer patientson August 6, 2020 at 6:44 am
Scientists have identified a gene which if present in certain breast cancer patients indicates how they will respond to specific therapies.
- Coronavirus Treatment: Alcohol Addiction, Breast Cancer Drugs Found Effective Against COVID-19on August 6, 2020 at 4:40 am
Researchers discovered a drug used against alcoholism is potentially able to "switch off" the enzyme key to coronavirus reproduction.
- The effect of reduced RDI of chemotherapy on the outcome of breast cancer patientson August 6, 2020 at 4:02 am
The aims of this study were to investigate the impact of the relative dose intensity (RDI) of chemotherapy on disease-free survival (DFS) and overall survival (OS), to identify the optimal RDI cut-off ...
- PRMT1-dependent methylation of BRCA1 contributes to the epigenetic defense of breast cancer cells against ionizing radiationon August 6, 2020 at 4:02 am
The therapeutic effect of irradiation is thought to come from DNA damage that affects rapidly proliferating cancer cells; however, resistant cells rapidly initiate mechanisms to repair such damage.
- HDAC6 inhibitors increase efficacy of immunotherapy in triple-negative breast canceron August 5, 2020 at 9:33 pm
Genetic modifier HDAC6 was found to control tumor growth and halt metastasis in triple-negative breast cancer in vivo, according to a new study published in the top-tier journal Cancer Research by ...
- Cheap, fast breast cancer test 100% accurate, study findson August 5, 2020 at 11:38 am
Researchers have developed a rapid and affordable test for breast cancer designed for use in developing regions, where patients often face long wait times for a diagnosis, negatively impacting their ...
- FemBeat: YC-Backed Liyfe Clinic Launches An Online Service To Provide Breast Cancer Patients With The Knowledge And Resources They Needon August 5, 2020 at 9:50 am
The latest startup to join the growing Femtech space is Liyfe Clinic, which provides breast cancer patients with information, consultations and support — from pre-diagnosis to post-treatment.
via Bing News